The instruction for medical use
of Flebodia medicine 600
the Trade name
of FLEBODIA 600
the International unlicensed
name Diosmin Dosage Form
of the Tablet, coated, 600 mg
One tablet contains
active agent – the diosmin granulated (equivalent to diosmin anhydrous) 600 mg
excipients: microcrystalline cellulose, talc, silicon dioxide colloidal anhydrous Aerosil R 972 type, stearic acid
structure of a cover: a protective film of Sepifilm 002 (a gipromelloza, cellulose microcrystalline, stearate makrogol 400), Sepisperse AP 5523 dye (propylene glycol, a gipromelloz, the titan dioxide (E171), Ponceau 4R on varnish of aluminum (E124), ferrous oxide red (E172), ferrous oxide black (E 172)), Opaglos 6000 (wax palm, beeswax, gummilak, alcohol of 96%)
of the Tablet of round shape, biconvex, coated pink color.
Kapillyarostabiliziruyushchy means, bioflavonoids.
The code of automatic telephone exchange C05CA03
Pharmacokinetics Quickly properties is soaked up from digestive tract, it is found in blood plasma in 2 hours after reception. The maximum concentration in blood plasma is reached in 5 hours after reception. Evenly is distributed and collects in all layers of a wall of venas cava and saphenas of the lower extremities, to a lesser extent – in kidneys, a liver, light and other fabrics. Selective accumulation of diosmin and/or its metabolites in venous vessels reaches a maximum by the 9th o’clock after reception and remains within 96 hours. It is removed with urine of 79%, with a stake – 11%, with bile – 2.4%.
Drug possesses flebotoniziruyushchy action: reduces extensibility of veins, raises a tone of veins (dose-dependent effect), reduces venous stagnation, improves a lymphatic drainage: raises a tone and frequency of reduction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure, improves microcirculation: increases capillary resistance (dose-dependent effect), reduces their permeability, reduces adhesion of leukocytes to a venous wall and their migration in paravenous fabrics, improves diffusion of oxygen and perfusion in skin fabric, possesses anti-inflammatory action. Strengthens vasoconstrictive effect of adrenaline, noradrenaline, blocks development of free radicals, synthesis of prostaglandins and thromboxane.
– a varicosity of the lower extremities
– chronic lympho-venous insufficiency of the lower extremities -hemorrhoids
– microcirculation disturbances
the Route of administration and doses
Inside. In a varicosity of the lower extremities and in an initial stage of chronic lympho-venous insufficiency (weight in legs) appoint on 1 tablet a day, in the morning till a breakfast within 2 months.
At severe forms of chronic lympho-venous insufficiency (hypostases, pains, spasms, etc.) – treatment is continued within 3 – 4 months, in the presence of trophic changes and ulcers the course is prolonged up to 6 months and more. The course is repeated in 2-3 months.
At exacerbation of hemorrhoids appoint 2-3 tablets a day at meal time within 7 days, further if necessary it is possible to continue on 1 tablet within 1 – 2 months once a day.
At treatment of chronic lympho-venous insufficiency during II and III trimester of pregnancy appoint on 1 tablet once a day.
If you missed one or several receptions continue use of drug in a usual dosage.
– hypersensitivity to drug components
– dispepsichesky disorders
– a headache.
– individual intolerance
– children’s age up to 18 years
of Clinically significant effects of interaction with other medicines is not described.
Strengthening of vasoconstrictive effect of adrenaline and noradrenaline is possible.
instructions Treatment of a Bad Attack of Hemorrhoids carry out in a complex with other drugs, in the absence of fast clinical effect it is necessary to perform additional examination and to correct the carried-out therapy.
There are data on possible efficiency of drug at treatment of fetoplacental insufficiency, for prevention of the bleedings arising at use of an intrauterine spiral and during the period after phlebectomy.
Pregnancy and a lactation
are not established negative influences of drug on a course of pregnancy and fetation.
For the period of treatment it is necessary to refuse breastfeeding since there is not enough information on penetration of components of drug into breast milk.
The feature of influence of drug on ability to run the vehicle or potentially dangerous mechanisms
does not influence.
Symptoms of overdose are not described.
A form of release and packing
On 15 tablets in blister strip packaging from a film of polyvinylchloride and aluminum foil. On the 1 or 2 blister strip packaging together with the instruction for medical use in the state and Russian languages place in a cardboard pack.
At a temperature not above 30 °C.
To store in the inaccessible place for children!
not to apply a period of storage after the expiration date specified on packing.
of Innotera Laboratory, it is made Innotera Shuzi, France,
Rue Rene Chantereau L ‘ Isle Vert, 41150, CHOUZY-SUR-CISSE, France
(Rue Rene Shantero L’Isl Ver, 41150, Shuzi-Sur-Cis, France).
The organization accepting from consumers of a claim (offer) on quality of drug in the territory of the Republic of Kazakhstan
Representation Innotek Internasional Laboratory of S.A.S. in RK
050059, Republic of Kazakhstan, Almaty, Al-Farabi Ave., 17, business center of Nurla Tau, the block of 4 B, office 606, ph./fax: +7-727-311-09-71, +7-727-311-09-72, e-mail: email@example.com